索磷布韦/维帕他韦联合利巴韦林治疗格卡瑞韦哌仑他韦治疗失败的 HCV 基因 1a、2a 或 3b 型患者
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
机构信息
Department of Hepatology, Graduate School of Medicine, Osaka City University, Japan.
出版信息
Intern Med. 2021 Nov 1;60(21):3441-3445. doi: 10.2169/internalmedicine.7028-21. Epub 2021 May 22.
Abstract
Glecaprevir/pibrentasvir (GLE/PIB) is a pan-genotype anti-hepatitis C virus (HCV) therapy with high efficacy and safety. However, evidence supporting retreatment following failure of the GLE/PIB regimen is limited. We herein report 3 non-cirrhotic cases involving two men aged 51 and 58 years old and a woman aged 68 years old infected with HCV genotype 1a, 2a, and 3b respectively who failed anti-HCV therapies including GLE/PIB therapy. With combination therapy of sofosbuvir/velpatasvir plus ribavirin (SOF/VEL+RBV) for 24 weeks, all 3 patients had achieved a sustained viral response (SVR) at 24 weeks after completing treatment. SOF/VEL+RBV therapy was effective for retreatment of HCV after failure of GLE/PIB therapy.
摘要
格卡瑞韦哌仑他韦（GLE/PIB）是一种泛基因型抗丙型肝炎病毒（HCV）治疗药物，具有高效和安全性。然而，支持 GLE/PIB 方案治疗失败后再治疗的证据有限。我们在此报告 3 例非肝硬化病例，涉及 2 名年龄分别为 51 岁和 58 岁的男性和 1 名年龄为 68 岁的女性，他们分别感染了 HCV 基因型 1a、2a 和 3b，之前曾接受过包括 GLE/PIB 疗法在内的抗 HCV 治疗失败。这 3 例患者均接受索磷布韦/维帕他韦加利巴韦林（SOF/VEL+RBV）联合治疗 24 周，治疗完成后 24 周均达到持续病毒学应答（SVR）。SOF/VEL+RBV 治疗对 GLE/PIB 治疗失败后的 HCV 再治疗是有效的。
相似文献
1
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.索磷布韦/维帕他韦联合利巴韦林治疗格卡瑞韦哌仑他韦治疗失败的 HCV 基因 1a、2a 或 3b 型患者
Intern Med. 2021 Nov 1;60(21):3441-3445. doi: 10.2169/internalmedicine.7028-21. Epub 2021 May 22.
2
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.索磷布韦/维帕他韦/沃西拉韦在既往接受索磷布韦/维帕他韦或格卡瑞韦/哌仑他韦治疗的丙型肝炎患者中的真实世界疗效。
Aliment Pharmacol Ther. 2024 Jul;60(2):201-211. doi: 10.1111/apt.18020. Epub 2024 May 2.
3
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.索磷布韦/维帕他韦和格卡瑞韦/哌仑他韦治疗慢性丙型肝炎 6 型的真实世界疗效和安全性。
J Formos Med Assoc. 2022 Nov;121(11):2265-2272. doi: 10.1016/j.jfma.2022.04.020. Epub 2022 May 14.
4
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.索磷布韦/维帕他韦±利巴韦林与格卡瑞韦/哌仑他韦治疗基因 3 型丙型肝炎病毒感染患者的疗效和安全性。
Eur J Hosp Pharm. 2020 Mar;27(e1):e41-e47. doi: 10.1136/ejhpharm-2019-002060. Epub 2020 Feb 7.
5
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].[格卡瑞韦/哌仑他韦+索磷布韦+利巴韦林作为索磷布韦+维帕他韦+伏西瑞韦再治疗失败后的挽救方案]
Z Gastroenterol. 2022 Jun;60(6):959-962. doi: 10.1055/a-1649-8931. Epub 2021 Oct 19.
6
Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.韩国 1 型和 2 型丙型肝炎病毒患者中 Glecaprevir/Pibrentasvir 和 Sofosbuvir/Ledipasvir 的比较。
Korean J Gastroenterol. 2024 Mar 25;83(3):111-118. doi: 10.4166/kjg.2023.141.
7
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.直接作用抗病毒药物治疗完成后慢性丙型肝炎基因型 2 感染患者的真实世界疗效。
Kaohsiung J Med Sci. 2021 Apr;37(4):334-345. doi: 10.1002/kjm2.12315. Epub 2020 Nov 5.
8
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.glecaprevir和pibrentasvir治疗丙型肝炎病毒1型感染及既往直接抗病毒治疗12周。
Hepatology. 2017 Aug;66(2):389-397. doi: 10.1002/hep.29081. Epub 2017 Apr 10.
9
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.在台湾的一项多中心汇总分析中，glecaprevir/pibrentasvir 和 ledipasvir/sofosbuvir 治疗混合基因型丙型肝炎感染的真实世界疗效。
J Viral Hepat. 2020 Sep;27(9):866-872. doi: 10.1111/jvh.13305. Epub 2020 May 12.
10
[A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].1例丙型肝炎病毒3b基因型代偿期肝硬化患者，曾两次接受glecaprevir/pibrentasvir联合索磷布韦和利巴韦林治疗16周。
Zhonghua Gan Zang Bing Za Zhi. 2021 Dec 20;29(12):1194-1195. doi: 10.3760/cma.j.cn501113-20200526-00275.
引用本文的文献
1
Treatment progress and expansion in Japan: From interferon to direct-acting antiviral.日本的治疗进展与拓展：从干扰素到直接作用抗病毒药物
Glob Health Med. 2021 Oct 31;3(5):321-334. doi: 10.35772/ghm.2021.01083.
本文引用的文献
1
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].《欧洲肝脏研究学会丙型肝炎治疗推荐：系列最终更新版》勘误 [《肝脏病学杂志》73卷（2020年）1170 - 1218页]
J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.
2
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).格卡瑞韦哌仑他韦治疗亚洲慢性丙型肝炎病毒感染：两项多中心、3 期研究-一项随机、双盲研究（VOYAGE-1）和一项开放标签、单臂研究（VOYAGE-2）。
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16.
3
Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection.索磷布韦、维帕他韦联合利巴韦林治疗对既往 DAA 治疗失败且伴有 NS5A-P32 缺失突变的 HCV 感染的慢性肝炎患者的真实疗效。
Clin J Gastroenterol. 2020 Dec;13(6):1233-1238. doi: 10.1007/s12328-020-01182-9. Epub 2020 Jul 12.
4
Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update.日本肝脏病学会丙型肝炎病毒感染管理指南：2019年更新版
Hepatol Res. 2020 Jul;50(7):791-816. doi: 10.1111/hepr.13503. Epub 2020 May 29.
5
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.在真实世界中，glecaprevir/pibrentasvir 治疗慢性丙型肝炎伴难治性因素患者的有效性和安全性：一项前瞻性多中心研究的综合分析。
Hepatol Int. 2020 Mar;14(2):225-238. doi: 10.1007/s12072-020-10019-z. Epub 2020 Mar 3.
6
Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients.系统评价和荟萃分析：基线耐药相关突变对慢性丙型肝炎患者使用格卡瑞韦哌仑他韦治疗效果的影响。
Aliment Pharmacol Ther. 2020 Mar;51(5):490-504. doi: 10.1111/apt.15633. Epub 2020 Jan 14.
7
Hepatitis C.丙型肝炎。
Lancet. 2019 Oct 19;394(10207):1451-1466. doi: 10.1016/S0140-6736(19)32320-7.
8
Intention-to-treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world.在现实世界中对glecaprevir + pibrentasvir联合疗法治疗慢性丙型肝炎患者进行意向性治疗评估。
Hepatol Res. 2019 Dec;49(12):1365-1373. doi: 10.1111/hepr.13410. Epub 2019 Aug 9.
9
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.在日本真实世界环境中，直接作用抗病毒药物初治非肝硬化 HCV 基因 1 型和 2 型感染患者 8 周 glecaprevir/pibrentasvir 治疗的评估。
J Viral Hepat. 2019 Nov;26(11):1266-1275. doi: 10.1111/jvh.13170. Epub 2019 Aug 9.
10
Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.格卡瑞韦哌仑他韦初治及再治日本慢性丙型肝炎病毒基因 1/2/3 型感染者的疗效。
J Gastroenterol. 2019 Oct;54(10):916-927. doi: 10.1007/s00535-019-01575-9. Epub 2019 Mar 22.
Zotero 插件